Methods: Systematic screening of Giardia-specific promoters and luciferase variants led to the 48 development of a strain expressing the click beetle green luciferase. Further modifying this strain 49 to express NanoLuc created a dual reporter strain capable of quantifying parasites in both the 50 trophozoite and cyst stages. These strains were used to develop a high throughput cell assay and 51 a mouse infection model. A library of MetRS inhibitors was screened in the cell assay and 1717 52 was tested for efficacy in the mouse infection model.
53
Results: Cell viability in in vitro compound screens was quantified via bioluminescence readouts 54 while infection loads in mice were monitored with noninvasive whole-animal imaging and fecal Introduction 67 Giardia lamblia infections are among the most common causes of chronic diarrhea in 68 children in resource-limited environments. New therapeutics are needed to address issues with 69 existing therapies including resistance, toxicity, and reduced efficacy. No vaccines have been 70 developed for clinical use, so case management depends solely on antimicrobial chemotherapy. 1 71 Current therapies approved by the Food and Drug Administration for giardiasis include 72 metronidazole and tinidazole. [2] [3] [4] However, approximately 20% of clinical cases involve 73 metronidazole-(and presumably tinidazole-) resistant Giardia. 5 Second-line drugs such as 74 albendazole, nitazoxanide, furazolidone, and paromomycin generally have lower efficacy rates 75 and/or potentially dangerous side effects. 6 All of these factors necessitate the development of a 76 new therapeutic, which requires various experimental tools for screening and verification of 77 efficacy of potential leads. 78 While experimental methods suitable for drug screening against G. lamblia have been 79 described in literature, 7 in vivo infection models in adult mice can benefit from an improved method 80 of monitoring infection. This deficiency of the in vivo model can be explained in part by earlier 81 studies showing instability in the expression of transgenes in Giardia compared to many other 82 eukaryotic cells. 8 The instability leads to variable expression as Giardia, by an unknown 83 mechanism, downregulates transgenic markers. 8 We recently described a luciferase-based 84 reporter system in G. lamblia WBC6 trophozoites for quantitative fluorescence readouts from a 85 red-shifted firefly luciferase reporter gene (PpyRE9h) under the control of the β-tubulin promoter 86 (pβTub). 9, 10 While the bioluminescent output of G. lamblia WBC6:pβTub::PpyRE9h was 87 sufficiently stable for 24-hour in vitro assays, it lacked long-term stability over multiple passages 88 and proved unsuitable for the mouse model of infection. In this study, we describe the 89 development of a new strain of G. lamblia using a click beetle green luciferase (CBG99) under a 90 short glutamate dehydrogenase promoter (pGDHS) that can be used for in vitro screens of 91 compound libraries and in vivo efficacy assays. A second strain was engineered by endogenously 92 tagging one copy of the cyst wall protein 1 (CWP1) gene with NanoLuc (Nluc) in the G. lamblia 93 WBC6:pGDHS::CBG99 strain, establishing a second developmentally induced reporter that 94 specifically measures cyst quantity. The strains can be visualized and measured in an animal 95 model of infection using noninvasive imaging to evaluate experimental drug effects in Giardia-96 infected animals. The developed mouse model was validated using the standard metronidazole 97 treatment and subsequently was used to confirm that G. lamblia methionyl-tRNA synthetase 98 (MetRS) enzyme inhibitor 1717 is a potential therapeutic alternative for treatment of clinical 99 giardiasis.
100

Materials and Methods
101
Plasmid construction and G. lamblia transfection:
To optimize luminescence of Giardia for in 102 vitro and in vivo experiments, various combinations of luciferase genes with Giardia-specific 103 promoters were tested. Twelve gene constructs were generated: three containing PpyRE9h 104 driven by three Giardia promoters, five containing various luciferase genes driven by the long 105 glutamate dehydrogenase promoter (pGDHL), and four containing CBG99 driven by four Giardia 106 promoters. The three PpyRE9h constructs were driven by pGDHL, the short glutamate 107 dehydrogenase promoter (pGDHS), 11 and the ornithine carboxytranferase promoter (pOCT). 12 108 These were amplified by PCR using the primers found in Table 1 and digested with EcoRI and   109 XbaI. The promoter fragments were cloned into the EcoRI-XbaI site of integration vector pPACV-110 integ. 10, 13 For the luciferase systems driven by pGDHL, the coding regions of the various 111 luciferase genes were amplified with the primers from Table 1 and digested with XbaI and PacI.   112 The XbaI-PacI fragments were cloned downstream of the promoter in the pPACV-integ vector's 113 XbaI-PacI cloning site. Selected luciferase genes included standard firefly luciferase (Fluc), firefly 114 luciferase 2 (Luc2), red click beetle luciferase (CBR), enhanced green-emitting luciferase (Eluc), 115 and CBG99. To generate the CBG99 constructs, the pGDHL, pGDHS, pOCT, and pβTub were 116 amplified with primers from were then precipitated with ethanol and incubated with 300 µL of chilled G. lamblia cells (~13x10 6 124 cells/mL) for 30 minutes before electroporation (Bio-Rad GenePulser X at 375 V, 1000 µF, 750 125 ohms). After electroporation, cells were incubated on ice for 10 minutes, then transferred to fresh 126 media at 37 o C. Transfectants were selected with puromycin after overnight recovery.
127
Parasite cultures: G. lamblia WBC6:pβTub::PpyRE9h and wild type (WBC6, ATCC 50803) 128 trophozoites were the starting strains used in these studies. 10 These and all the newly transfected 129 strains were grown in TYI-S-33 medium supplemented with 10% bovine serum and 0.05 mg/mL 130 bovine bile without (wild type WBC6) or with (transfected strains) antibiotic selection pressure of 131 32 µg/mL puromycin dihydrochloride (Gibco, Dublin, Ireland). 10, 14 Cultures were incubated at 132 37°C in 16 mL Falcon round bottom polystyrene test tubes (Corning Inc., Corning, NY).
133
G. lamblia trophozoite in vitro bioluminescence optimization:
The optimum concentration of 134 luminescent substrate, D-Luciferin (GoldBio, USA), required for cell identification was determined 135 as earlier described. 10 AkaLumine (a D-Luciferin analog that is not recognized by the CBG99 136 enzyme) was used as a control. 15, 16 Plates were incubated for 5, 10, 15, 30, 60, 90, 120, 150, 137 and 180 minutes at room temperature. Parasite numbers were correlated with bioluminescence 138 intensity by plating a two-fold serial dilution of cells. 10 Plates were read with an EnVision Multilabel 139 Plate Reader (Perkin Elmer, USA) after incubation at room temperature. Assays were repeated 140 on different days at least twice. were added to the bottom to prepare for luminescence reading. Ten µL of 2.5 mg/mL D-Luciferin 156 was added to each well and the reaction was incubated at room temperature for 5 minutes on a 157 shaker protected from light. Luminescence was read with an EnVision Plate Reader. 10 Response 158 curves and EC50 values (the concentration at which cell growth is inhibited by 50%) were 159 calculated using GraphPad Prism 6 (GraphPad, LaJolla, CA). All assays were repeated on 160 different days. Figure 1A ). We speculated that this would not be bright enough for use in a mouse model of 209 infection, where the luminescent signal must penetrate multiple layers of tissue to visualize 210 infection noninvasively. There also appeared to be a fitness cost for cells with the pOCT-driven 211 luciferase exhibited by a decrease in growth rate. Thus, further work was needed to establish a 212 brighter and more stable luciferase reporter system in G. lamblia. Earlier studies had 213 demonstrated that Fluc, Luc2, and CBR had higher sensitivity than PpyRE9h to report promoter 214 activity in other systems. 21, 22 Hence, these red luciferases were assayed in Giardia. 215 The red luciferase genes PpyRE9h, Fluc, Luc2, and CBR inserted downstream of pGDHL 216 were transfected into G. lamblia WBC6 cells. Among the resultant strains, trophozoites with the 217 Fluc gene had the brightest signal intensity, followed by those with the Luc2 gene ( Figure 1B) . 218 Two green luciferase emitting genes, CBG99 and ELuc, previously shown to exhibit higher levels 219 of bioluminescence than Fluc, 23, 24 were also assayed for higher signals under the control of 220 pGDHL. In our study, G. lamblia WBC6:pGDHL::CBG99 was 100-fold brighter in signal intensity 221 than G. lamblia WBC6:pGDHL::Eluc. We conclude that G. lamblia WBC6:pGDHL::CBG99 is the 222 brightest luciferin-based reporter system among the red and green luciferases tested ( Figure 1B) . Figure 1C ). However, G. lamblia strains 228 expressing the CBG99 luciferase driven by pβTub, pOCT and pGDHL promoters have substantial 229 fitness disadvantages in their rate of growth and proliferation relative to the wild type strain. The 230 effect was least pronounced with the G. lamblia WBC6:pGDHS::CBG99 ( Figure 1D ). Though it 231 had the lowest signal of the promoters tested with CBG99, the signal intensity was still several 232 fold brighter than the one given by pGDHS::PpyRE9h, and therefore it was more suitable for the 233 drug screening assays and murine model development. (Figure 2A) . The blank media control wells 242 showed no luminescence as compared to the empty background wells and to the sample wells. 243 AkaLumine showed no signal at any time point, as expected. The average Z' of this assay was 244 0.6.
245
G. lamblia luciferase expression stability:
In our previous study, the bioluminescent signal of 246 G. lamblia WBC6:pβTub::PpyRE9h was the same as the wild type G. lamblia WBC6 after three 247 weeks of incubation, suggesting a loss of the luciferase gene activity. Therefore, we tested for 248 signal stability in the G. lamblia WBC6:pGDHS::CBG99 cells in the absence of the selection 249 antibiotic, puromycin. After four weeks without antibiotic, the bioluminescent signal of G. lamblia 250 WBC6:pGDHS::CBG99 was detected in sufficiently high levels to be called stable expression. 251 The signal was 35 times brighter than that given by G. lamblia WBC6:pβTub::PpyRE9h cells after 252 the same amount of time, which shows no differentiable signal compared to the wild type ( Figure   253 2B). This is especially important to guarantee robust detection of the bioluminescent signal for an 254 in vivo experimental model of chronic infection lasting over 3 weeks.
255
Screening of MetRS inhibitors including compound 1717:
The initial MetRS inhibitor screen 256 at 20 μM proved to be highly potent against the parasites, with inhibition rates >98% across most 257 compounds. The concentration was subsequently dropped to 2 μM, where most compounds still 258 had potent inhibition ( Figure 3A , Table 2 ). Compounds BKI1708 and BKI1770, which are highly 259 selective inhibitors of apicomplexan calcium dependent protein kinases not found in G. lamblia, 260 were included in the screens as negative controls. 25 The low inhibition rates of BKI1708 and 261 BKI1770 at both concentrations demonstrate the specificity of the assay. Percentage inhibition 262 data from the compound screens are presented below (Table 2) . 263 The 2 μM screen in 384-well plates with G. lamblia WBC6:pGDHS::CBG99 and G. lamblia 264 WBC6:pGDHS::CBG/Nluc had average Z' values of 0.7 and 0.6, respectively. The screening data 265 shows that these compounds exhibit a similar inhibition profile against both strains ( Figure 3A) . 266 Compound 1717 has previously shown potent inhibition on Giardia MetRS enzyme (GlMetRS) 267 activity and its EC50 was determined to be 453 nM. 26 The EC50 of 1717 for G. lamblia infection and clearance during in vivo assays, we attempted to measure luminescence in G. 295 lamblia WBC6:pGDHS::CBG99 cysts from fecal samples. There was no detectable luminescence 296 even in our untreated infected controls. This is likely because the cyst wall, which protects cysts 297 from rupturing in water, prevents the uptake of D-Luciferin. To improve upon this reporter strain, 298 we endogenously tagged the CWP1 gene of the G. lamblia WBC6:pGDHS::CBG99 strain with 299 Nluc. A plot of bioluminescence outputs from cysts of G. lamblia WBC6:pGDHS::CBG99 versus 300 WBC6:pGDHS::CBG/Nluc using NanoGlo is presented in Figure 5A . The growth and proliferation 301 rate of the 2 strains was experimentally compared and shown to be similar ( Figure 5B ). administration of puromycin to maintain selective pressure. We earlier determined that Nluc is 312 approximately 17 times brighter than CBG99 when driven by the same promoter (not shown). 313 Since mice shed relatively few cysts during infection, a more sensitive luciferase is required to 314 validate infection or clearance in experimental drug studies, which makes Nluc a good choice.
315
CBG99 is a better cell viability reporter as it requires the presence of ATP for luminescence and 316 therefore will not produce light in dead cells. That Nluc does not require ATP for luminescence 317 makes it a viable reporter for the cyst stage when cells are relatively dormant. Hence, Nluc was 318 not considered as an alternative to CBG99 but rather as a supplement. Additionally, fusing Nluc 319 to CWP1, which is secreted to form the cyst wall, eliminates the need for luminescent substrate 320 to travel through the cyst wall barrier in order to reach the luciferase. This modification will provide 321 the ability to follow total parasite load in animals as well as easily quantify cyst production. 322 We demonstrated the usefulness of the luciferase reporter system to evaluate treatment 323 with compound 1717 in a mouse model of giardiasis using the noninvasive IVIS Spectrum optical 324 imaging system. Compound 1717, a fluoro-imidazopyridine, is one of a new class of inhibitors that 325 stop protein synthesis by targeting parasitic MetRS as previously described. 26 These inhibitors 326 are lethal to G. lamblia parasites but nontoxic to mammalian cells in cell based assays. 26 Chemical 327 synthesis, pharmacokinetics, cytotoxicity, and inhibitory activity of compound 1717 on the wild 328 type G. lamblia WBC6 strain and the GlMetRS enzyme were previously described. 26, 32, 33 Analysis 329 of 1717's pharmacokinetic profile showed that a single 50 mg/kg oral dose in mice would have 330 sufficient gut and systemic levels to be effective for treatment of mouse giardiasis. 33 The 331 compound is about 8 times more potent than metronidazole, which has an EC50 of 5 µM. 26 Tween 80 in normal saline) as a control. Imaging on day 8 post infection (D4) showed that 1717 and 487 metronidazole cleared the infection relative to the untreated controls (VEH). The plot of the 488 intensity/radiance data before therapy against days after start of treatment showed a significant drop 489 relative to untreated controls. * Note that images for some groups of mice on D1 have been cut together. 490 This is due in part to differential intensity of the luminescence signal obtained from some mice hence 491 differences in the length of time needed to acquire images that confirmed established infection. All images 492 were taken during the same session and were scaled together. 
